Nitric oxide synthase inhibition attenuates cutaneous vasodilation during postmenopausal hot flash episodes

Kimberly A. Hubing, Jonathan E. Wingo, R. Matthew Brothers, Juan Del Coso, David A. Low, Craig G. Crandall

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The purpose of this study was to test the hypothesis that local inhibition of nitric oxide and prostaglandin synthesis attenuates cutaneous vasodilator responses during postmenopausal hot flash episodes. Methods: Four microdialysis membranes were inserted into the forearm skin (dorsal surface) of eight postmenopausal women (mean ± SD age, 51 ± 7 y). Ringer solution (control), 10 mM ketorolac (Keto) to inhibit prostaglandin synthesis, 10 mM N-l-arginine methyl ester (l-NAME) to inhibit nitric oxide synthase, and a combination of 10 mM Keto + 10 mM l-NAME were each infused at the separate sites. Skin blood flow at each site was indexed using laser-Doppler flowmetry. Cutaneous vascular conductance (CVC) was calculated as laser-Doppler flux/mean arterial blood pressure and was expressed as a percentage of the maximal calculated CVC (CVCmax) obtained after infusion of 50 mM sodium nitroprusside at all sites at the end of the study. Data from 13 hot flash episodes were analyzed. Results: At the control site, the mean ± SD peak increase in CVC was 15.5% ± 6% CVCmax units. This value was not different relative to the peak increase in CVC at the Keto site (13.0% ± 5% CVCmax units; P = 0.09). However, the peak increase in CVC during hot flash episodes were attenuated at the l-NAME and l-NAME + Keto sites (7.4% ± 4% and 8.7% ± 7% CVCmax units, respectively) relative to both the control and the Keto sites (P < 0.05 for both comparisons). There were no significant differences in the peak increases in sweat rate between any of the sites (P = 0.24). Conclusions: These data demonstrate that the mechanism for cutaneous vasodilation during hot flash episodes has a nitric oxide component. Increases in CVC despite the inhibition of prostaglandin synthesis suggest that prostaglandins do not contribute to cutaneous vasodilation during hot flash episodes.

Original languageEnglish (US)
Pages (from-to)978-982
Number of pages5
JournalMenopause
Volume17
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Hot Flashes
Vasodilation
Nitric Oxide Synthase
Ketorolac
Skin
Blood Vessels
Prostaglandins
Arterial Pressure
Nitric Oxide
Laser-Doppler Flowmetry
Sweat
Microdialysis
Nitroprusside
Vasodilator Agents
Forearm
Lasers

Keywords

  • Cutaneous vasodilation
  • Hot flash
  • Nitric oxide
  • Skin blood flow

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Nitric oxide synthase inhibition attenuates cutaneous vasodilation during postmenopausal hot flash episodes. / Hubing, Kimberly A.; Wingo, Jonathan E.; Brothers, R. Matthew; Del Coso, Juan; Low, David A.; Crandall, Craig G.

In: Menopause, Vol. 17, No. 5, 09.2010, p. 978-982.

Research output: Contribution to journalArticle

Hubing, Kimberly A. ; Wingo, Jonathan E. ; Brothers, R. Matthew ; Del Coso, Juan ; Low, David A. ; Crandall, Craig G. / Nitric oxide synthase inhibition attenuates cutaneous vasodilation during postmenopausal hot flash episodes. In: Menopause. 2010 ; Vol. 17, No. 5. pp. 978-982.
@article{e5ab0b85dbf24a47821335b5a310aeba,
title = "Nitric oxide synthase inhibition attenuates cutaneous vasodilation during postmenopausal hot flash episodes",
abstract = "Objective: The purpose of this study was to test the hypothesis that local inhibition of nitric oxide and prostaglandin synthesis attenuates cutaneous vasodilator responses during postmenopausal hot flash episodes. Methods: Four microdialysis membranes were inserted into the forearm skin (dorsal surface) of eight postmenopausal women (mean ± SD age, 51 ± 7 y). Ringer solution (control), 10 mM ketorolac (Keto) to inhibit prostaglandin synthesis, 10 mM N-l-arginine methyl ester (l-NAME) to inhibit nitric oxide synthase, and a combination of 10 mM Keto + 10 mM l-NAME were each infused at the separate sites. Skin blood flow at each site was indexed using laser-Doppler flowmetry. Cutaneous vascular conductance (CVC) was calculated as laser-Doppler flux/mean arterial blood pressure and was expressed as a percentage of the maximal calculated CVC (CVCmax) obtained after infusion of 50 mM sodium nitroprusside at all sites at the end of the study. Data from 13 hot flash episodes were analyzed. Results: At the control site, the mean ± SD peak increase in CVC was 15.5{\%} ± 6{\%} CVCmax units. This value was not different relative to the peak increase in CVC at the Keto site (13.0{\%} ± 5{\%} CVCmax units; P = 0.09). However, the peak increase in CVC during hot flash episodes were attenuated at the l-NAME and l-NAME + Keto sites (7.4{\%} ± 4{\%} and 8.7{\%} ± 7{\%} CVCmax units, respectively) relative to both the control and the Keto sites (P < 0.05 for both comparisons). There were no significant differences in the peak increases in sweat rate between any of the sites (P = 0.24). Conclusions: These data demonstrate that the mechanism for cutaneous vasodilation during hot flash episodes has a nitric oxide component. Increases in CVC despite the inhibition of prostaglandin synthesis suggest that prostaglandins do not contribute to cutaneous vasodilation during hot flash episodes.",
keywords = "Cutaneous vasodilation, Hot flash, Nitric oxide, Skin blood flow",
author = "Hubing, {Kimberly A.} and Wingo, {Jonathan E.} and Brothers, {R. Matthew} and {Del Coso}, Juan and Low, {David A.} and Crandall, {Craig G.}",
year = "2010",
month = "9",
doi = "10.1097/gme.0b013e3181d674d6",
language = "English (US)",
volume = "17",
pages = "978--982",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nitric oxide synthase inhibition attenuates cutaneous vasodilation during postmenopausal hot flash episodes

AU - Hubing, Kimberly A.

AU - Wingo, Jonathan E.

AU - Brothers, R. Matthew

AU - Del Coso, Juan

AU - Low, David A.

AU - Crandall, Craig G.

PY - 2010/9

Y1 - 2010/9

N2 - Objective: The purpose of this study was to test the hypothesis that local inhibition of nitric oxide and prostaglandin synthesis attenuates cutaneous vasodilator responses during postmenopausal hot flash episodes. Methods: Four microdialysis membranes were inserted into the forearm skin (dorsal surface) of eight postmenopausal women (mean ± SD age, 51 ± 7 y). Ringer solution (control), 10 mM ketorolac (Keto) to inhibit prostaglandin synthesis, 10 mM N-l-arginine methyl ester (l-NAME) to inhibit nitric oxide synthase, and a combination of 10 mM Keto + 10 mM l-NAME were each infused at the separate sites. Skin blood flow at each site was indexed using laser-Doppler flowmetry. Cutaneous vascular conductance (CVC) was calculated as laser-Doppler flux/mean arterial blood pressure and was expressed as a percentage of the maximal calculated CVC (CVCmax) obtained after infusion of 50 mM sodium nitroprusside at all sites at the end of the study. Data from 13 hot flash episodes were analyzed. Results: At the control site, the mean ± SD peak increase in CVC was 15.5% ± 6% CVCmax units. This value was not different relative to the peak increase in CVC at the Keto site (13.0% ± 5% CVCmax units; P = 0.09). However, the peak increase in CVC during hot flash episodes were attenuated at the l-NAME and l-NAME + Keto sites (7.4% ± 4% and 8.7% ± 7% CVCmax units, respectively) relative to both the control and the Keto sites (P < 0.05 for both comparisons). There were no significant differences in the peak increases in sweat rate between any of the sites (P = 0.24). Conclusions: These data demonstrate that the mechanism for cutaneous vasodilation during hot flash episodes has a nitric oxide component. Increases in CVC despite the inhibition of prostaglandin synthesis suggest that prostaglandins do not contribute to cutaneous vasodilation during hot flash episodes.

AB - Objective: The purpose of this study was to test the hypothesis that local inhibition of nitric oxide and prostaglandin synthesis attenuates cutaneous vasodilator responses during postmenopausal hot flash episodes. Methods: Four microdialysis membranes were inserted into the forearm skin (dorsal surface) of eight postmenopausal women (mean ± SD age, 51 ± 7 y). Ringer solution (control), 10 mM ketorolac (Keto) to inhibit prostaglandin synthesis, 10 mM N-l-arginine methyl ester (l-NAME) to inhibit nitric oxide synthase, and a combination of 10 mM Keto + 10 mM l-NAME were each infused at the separate sites. Skin blood flow at each site was indexed using laser-Doppler flowmetry. Cutaneous vascular conductance (CVC) was calculated as laser-Doppler flux/mean arterial blood pressure and was expressed as a percentage of the maximal calculated CVC (CVCmax) obtained after infusion of 50 mM sodium nitroprusside at all sites at the end of the study. Data from 13 hot flash episodes were analyzed. Results: At the control site, the mean ± SD peak increase in CVC was 15.5% ± 6% CVCmax units. This value was not different relative to the peak increase in CVC at the Keto site (13.0% ± 5% CVCmax units; P = 0.09). However, the peak increase in CVC during hot flash episodes were attenuated at the l-NAME and l-NAME + Keto sites (7.4% ± 4% and 8.7% ± 7% CVCmax units, respectively) relative to both the control and the Keto sites (P < 0.05 for both comparisons). There were no significant differences in the peak increases in sweat rate between any of the sites (P = 0.24). Conclusions: These data demonstrate that the mechanism for cutaneous vasodilation during hot flash episodes has a nitric oxide component. Increases in CVC despite the inhibition of prostaglandin synthesis suggest that prostaglandins do not contribute to cutaneous vasodilation during hot flash episodes.

KW - Cutaneous vasodilation

KW - Hot flash

KW - Nitric oxide

KW - Skin blood flow

UR - http://www.scopus.com/inward/record.url?scp=77957723411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957723411&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e3181d674d6

DO - 10.1097/gme.0b013e3181d674d6

M3 - Article

VL - 17

SP - 978

EP - 982

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 5

ER -